The role of cost-consequence analysis in healthcare decision-making

PharmacoEconomics

Volumn 13, Issue 3, 1998, Pages 277-288

  Mauskopf, Josephine A ^a,b   Paul, John E ^b   Grant, David M ^c   Stergachis, Andy ^d  

^a RTI INTERNATIONAL   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COST; HEALTH CARE PLANNING; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE MANAGEMENT; REVIEW;

COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; HUMANS;

EID: 0031913854     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813030-00002     Document Type: Review

References (32)

1. Organization for Economic Cooperation and Development (OECD). OECD health data 1996. Washington, DC: OECD, 1996
2. Government Accounting Office (GAO). Health care spending control: the experience of France, Germany, and Japan. Washington. DC: GAO, 1991. Publication no.: GAO/HRD-92-9
3. Government Accounting Office (GAO). German health reforms: changes result in lower health costs in 1993. Washington DC: GAO, 1994. Publication no.: GAO/HEHS-95-27
4. Schieber GJ, Poullier JP, Greenwald LM. US health expenditure performance: an international comparison and data update. Health Care Financ Rev 1992; 13: 1-15
5. Drummond MF, Stoddart GI, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
6. Bootman L, Townsend R, McGrath W. Principles of pharmacoeconomics. 2nd ed. Cincinnati (OH): Harvey Whitney Books Company, 1996
7. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1172-7
8. Davies L, Coyle D, Drummond M, et al. Current status of economic appraisal of health technology in the European Community: report of the network. Soc Sci Med 1994; 38: 16011-7
9. Canadian Coordinating Office on Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals. 1st ed. Ottawa: CCOHTA, 1994
10. Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Canberra: Australian Government Publishing Service, 1992
11. Soumerai SB, Ross-Degas D, Avorn J, et al. Effects of Medicaid drug payment limits on admission to hospitals and nursing homes. N Engl J Med 1991; 325: 1072-7
12. Schwartz RM, Luby AM, Scanlon JW, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500g. N Engl J Med 1994; 330: 1476-80
13. Backhouse ME, Mauskopf JA, Jones D, et al. Economic outcomes of synthetic surfactant rescue therapy in infants weighing 1250g or more with respiratory stress syndrome: results from a randomized trial. Pharmacoeconomics 1994; 6 (4): 358-69
14. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995; 333: 889-93
15. Greenberg PE, Stigli EL, Finkelstein SN, et al. The economic burden of depression. J Clin Psychiatry 1993; 54: 405-18
16. Drummond M. Cost-of-illness studies: a major headache. Pharmacoeconomics 1992; 2 (1): 1-4
17. Koopmanschap MA, Vanlnveld B. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 1005-10
18. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986; 76: 392-6
19. Stergachis A. Overview of cost-consequence modeling in outcomes research. Pharmacotherapy 1995; 15 (5 Pt 2): 40S-2S
20. Mauskopf JA, Schulman K, Bell L, et al. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials. Pharmacoeconomics 1996; 9 (3): 264-77
21. Drummond M, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-73
22. Paul JE, Tilson HH. Use and opportunities for administrative data bases in pharmacoeconomic research. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996
23. Hlatky MA, Califf RM, Harrell FE, et al. Comparisons of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Card 1988; 11: 237-45
24. Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Aff 1996; 15: 168-76
25. Handley MR, Stuart ME. All evidence-based approach to evaluating and improving clinical practice: guideline development. HMO Pract 1994; 8: 11-20
26. Lieu AT, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375-81
27. Platt R, Zaleznik DF, Hopkins DD et al. Perioperative antibiotic prophylaxis for horniorrhaphy and breast surgery. N Engl J Med 1990; 322: 153-60
28. Testa MA, Anderson RB, Nackley JF. Quality of Life Hypertension Study Group. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril. N Engl J Med 1993; 328: 907-13
29. Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella-zoster virus infections. Pharmacotherapy 1995; 15 (5 Pt 2): 49S-58S
30. Grant DM, Mauskopf JA, Bell L, et al. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Pharmacotherapy 1997; 17: 333-41
31. Bozzette AS, Kanouse DE, Berry S, et al. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. JAMA 1995; 273: 295-301
32. Aberg-Wistedt A, Cressell T, Lidberg Y, et al. Two-year outcome of team-based intensive case management for patients with schizophrenia. Psychiatr Serv 1995; 46: 1263-6